Xarelto Lawsuit Cases In MDL 2592 Move Closer To Trial

July 03, 2016 – – TheProductLawyers.com reports on progress of the multidistrict litigation (MDL) No. 2592 against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson.) Late in 2015, the more than 2,800 plaintiffs collectively petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) for an order of consolidation. Allegations held in common include an undue risk of harm associated with the use of Xarelto and suggest the anticoagulant is responsible for injuries sustained.

Issuing their approval in December, the JPML cited conservation of resources for all parties and expedition of the judicial process as the foundation of its verdict. In order to avoid the confusion of multiple verdicts, they also appointed Judge Eldon Fallon to oversee MDL 2592 in the Eastern District of Louisiana. Currently, all parties are in the process of selecting bellwether cases for trial, a measure intended to further expedite the legal proceedings once the MDL cases go to court.

In 2011, the U.S. Food and Drug Administration granted Xarelto approval. The drug was intended primarily as a clot preventative in individuals recovering from hip or knee replacement surgeries as well as a treatment option for pulmonary embolism or deep vein thrombosis. Soon after, it was approved for use as a stroke preventative in individuals suffering from atrial fibrillation. Initially, both the public and medical circles hailed the new-generation anticoagulant as a miracle drug, but that attitude has largely shifted.

Many individuals claim that using Xarelto exposed them to an elevated risk of catastrophic bleeding episodes, which would necessitate drastic medical intervention. Further, they assert that the episodes caused lasting damage that either requires continued care or results in death. The plaintiffs of MDL 2592 contend that the drug companies responsible for manufacturing and distributing Xarelto are guilty of negligence because they failed to adequately warn the public and the medical community of these potential risks.

In addition to the parties represented by the MDL, a mass tort program of 550 individual suits is scheduled to appear before the Philadelphia Court of Common Pleas. The plaintiffs of MDL 2592 feel confident that, as their cases move closer to court dates, more individuals will come forward seeking justice for alleged harm.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011167